120 related articles for article (PubMed ID: 24887313)
1. Synergistic activity of tenofovir and nevirapine combinations released from polycaprolactone matrices for potential enhanced prevention of HIV infection through the vaginal route.
Dang NT; Sivakumaran H; Harrich D; Shaw PN; Davis-Poynter N; Coombes AG
Eur J Pharm Biopharm; 2014 Oct; 88(2):406-14. PubMed ID: 24887313
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of polycaprolactone matrices for sustained vaginal delivery of nevirapine in the prevention of heterosexual HIV transmission.
Dang N; Sivakumaran H; Harrich D; Shaw PN; Coombes AGA
J Pharm Sci; 2014 Jul; 103(7):2107-2115. PubMed ID: 24867411
[TBL] [Abstract][Full Text] [Related]
3. An evaluation of polycaprolactone matrices for vaginal delivery of the antiviral, tenofovir, in preventing heterosexual transmission of HIV.
Dang NT; Sivakumaran H; Harrich D; Coombes AG
J Pharm Sci; 2013 Oct; 102(10):3725-35. PubMed ID: 23904196
[TBL] [Abstract][Full Text] [Related]
4. Durable protection from vaginal simian-human immunodeficiency virus infection in macaques by tenofovir gel and its relationship to drug levels in tissue.
Dobard C; Sharma S; Martin A; Pau CP; Holder A; Kuklenyik Z; Lipscomb J; Hanson DL; Smith J; Novembre FJ; García-Lerma JG; Heneine W
J Virol; 2012 Jan; 86(2):718-25. PubMed ID: 22072766
[TBL] [Abstract][Full Text] [Related]
5. Quantitative evaluation of a hydrophilic matrix intravaginal ring for the sustained delivery of tenofovir.
Clark JT; Johnson TJ; Clark MR; Nebeker JS; Fabian J; Tuitupou AL; Ponnapalli S; Smith EM; Friend DR; Kiser PF
J Control Release; 2012 Oct; 163(2):240-8. PubMed ID: 22981701
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and topical vaginal effects of two tenofovir gels in rabbits.
Clark MR; Friend DR
AIDS Res Hum Retroviruses; 2012 Nov; 28(11):1458-66. PubMed ID: 22394281
[TBL] [Abstract][Full Text] [Related]
7. Manufacturing scale-up of electrospun poly(vinyl alcohol) fibers containing tenofovir for vaginal drug delivery.
Krogstad EA; Woodrow KA
Int J Pharm; 2014 Nov; 475(1-2):282-91. PubMed ID: 25169075
[TBL] [Abstract][Full Text] [Related]
8. A 90-day tenofovir reservoir intravaginal ring for mucosal HIV prophylaxis.
Johnson TJ; Clark MR; Albright TH; Nebeker JS; Tuitupou AL; Clark JT; Fabian J; McCabe RT; Chandra N; Doncel GF; Friend DR; Kiser PF
Antimicrob Agents Chemother; 2012 Dec; 56(12):6272-83. PubMed ID: 23006751
[TBL] [Abstract][Full Text] [Related]
9. Simultaneous delivery of tenofovir and acyclovir via an intravaginal ring.
Moss JA; Malone AM; Smith TJ; Kennedy S; Kopin E; Nguyen C; Gilman J; Butkyavichene I; Vincent KL; Motamedi M; Friend DR; Clark MR; Baum MM
Antimicrob Agents Chemother; 2012 Feb; 56(2):875-82. PubMed ID: 22123689
[TBL] [Abstract][Full Text] [Related]
10. Increased Dapivirine tissue accumulation through vaginal film codelivery of dapivirine and Tenofovir.
Akil A; Devlin B; Cost M; Rohan LC
Mol Pharm; 2014 May; 11(5):1533-41. PubMed ID: 24693866
[TBL] [Abstract][Full Text] [Related]
11. Development of a combination microbicide gel formulation containing IQP-0528 and tenofovir for the prevention of HIV infection.
Ham AS; Ugaonkar SR; Shi L; Buckheit KW; Lakougna H; Nagaraja U; Gwozdz G; Goldman L; Kiser PF; Buckheit RW
J Pharm Sci; 2012 Apr; 101(4):1423-35. PubMed ID: 22227864
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of polycaprolactone matrices for the intravaginal delivery of metronidazole in the treatment of bacterial vaginosis.
Pathak M; Turner M; Palmer C; Coombes AG
J Biomater Appl; 2014 Sep; 29(3):354-63. PubMed ID: 24682036
[TBL] [Abstract][Full Text] [Related]
13. Triple combination of carbosilane dendrimers, tenofovir and maraviroc as potential microbicide to prevent HIV-1 sexual transmission.
Sepúlveda-Crespo D; Sánchez-Rodríguez J; Serramía MJ; Gómez R; De La Mata FJ; Jiménez JL; Muñoz-Fernández MÁ
Nanomedicine (Lond); 2015; 10(6):899-914. PubMed ID: 25867856
[TBL] [Abstract][Full Text] [Related]
14. Delivery of multipurpose prevention drug combinations from electrospun nanofibers using composite microarchitectures.
Blakney AK; Krogstad EA; Jiang YH; Woodrow KA
Int J Nanomedicine; 2014; 9():2967-78. PubMed ID: 24971008
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of microporous polycaprolactone matrices for controlled delivery of antiviral microbicides to the female genital tract.
Asvadi NH; Dang NT; Davis-Poynter N; Coombes AG
J Mater Sci Mater Med; 2013 Dec; 24(12):2719-27. PubMed ID: 23892484
[TBL] [Abstract][Full Text] [Related]
16. Design of tenofovir-UC781 combination microbicide vaginal gels.
Kiser PF; Mahalingam A; Fabian J; Smith E; Damian FR; Peters JJ; Katz DF; Elgendy H; Clark MR; Friend DR
J Pharm Sci; 2012 May; 101(5):1852-64. PubMed ID: 22359356
[TBL] [Abstract][Full Text] [Related]
17. Dead-end complexes contribute to the synergistic inhibition of HIV-1 RT by the combination of rilpivirine, emtricitabine, and tenofovir.
Kulkarni R; Feng JY; Miller MD; White KL
Antiviral Res; 2014 Jan; 101():131-5. PubMed ID: 24291780
[TBL] [Abstract][Full Text] [Related]
18. Sustained local delivery of structurally diverse HIV-1 microbicides released from sublimation enthalpy controlled matrices.
Gunaseelan S; Gallay PA; Bobardt MD; Dezzutti CS; Esch T; Maskiewicz R
Pharm Res; 2012 Nov; 29(11):3156-68. PubMed ID: 22736232
[TBL] [Abstract][Full Text] [Related]
19. Development of intra-vaginal matrices from polycaprolactone for sustained release of antimicrobial agents.
Dang NT; Turner MS; Coombes AG
J Biomater Appl; 2013 Jul; 28(1):74-83. PubMed ID: 22684517
[TBL] [Abstract][Full Text] [Related]
20. Antiviral and immunological effects of tenofovir microbicide in vaginal herpes simplex virus 2 infection.
Vibholm L; Reinert LS; Søgaard OS; Paludan SR; Østergaard L; Tolstrup M; Melchjorsen J
AIDS Res Hum Retroviruses; 2012 Nov; 28(11):1404-11. PubMed ID: 22867119
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
